
Joshua Brody/LinkedIn
Apr 15, 2025, 13:28
Joshua Brody: Combining lymphoma immunotherapy with Standard of Care
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, shared an article on LinkedIn:
“Quick and insightful Commentary by Professor Carlo-Stella on our recent Blood paper on combining lymphoma immunotherapy with Standard of Care.”
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Authors: Joshua D. Brody, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 13:28
Apr 15, 2025, 13:00